Cookie Policy - To find out more about cookies on this website, see our privacy policy

Cookie Policy

We Help Companies Find New Sales Opportunities

We Help Companies Find New Sales Opportunities

Chemicals & Pharmaceuticals - 2001






















Cyprotex is planning to raise up to £11m in a flotation on Aim to invest in the launch of robotic testing equipment and software for use by pharmaceutical companies in the development of new drugs.

Avecia is planning to sell Stahl, the Dutch supplier of leather finishing chemicals with 1,500 staff in 28 countries, to a management buy-out for £232m.

Intercare has acquired Federa France, the French contract manufacturer of injectable pharmaceuticals with 137 staff, from Fresenius Kabi for £0.6m.

Unilever has sold Unipath, the Bedford-based women's health diagnostics business with 500 staff, to Inverness Medical Innovations of the US for £103m.

Close Brothers Private Equity and International Flavours & Fragrances have acquired the Bush Boake Allen site in Widnes, which produces fragrances and agricultural chemicals, securing the future of 80 jobs.

Synaptica has raised £3.5m of venture capital to fund the development of drugs for neurodegenerative disorders.

Scottish Enterprise is forming a partnership with Medical Marketing International to set up a £15m business incubator for nanotechnology and biotechnology at the Alba Campus in Livingston, which will create up to 500 jobs.

GlaxoSmithKline is to collaborate with Roche of Switzerland on the development of the Ibandronate treatment for osteoporosis, which is expected to reach the market in 2004.

Acambis has secured a £28m capital injection from Baxter Healthcare to fund the refurbishment of a US plant to produce the smallpox vaccine.

Bioglan is selling its GenPlus generics telesales business in Waterlooville to Ethercorp for a nominal sum, in order to focus on dermatology and the development of the Biosphere drug delivery system.

Peakdale Molecular, the supplier of chemical research services to the pharmaceutical industry, has secured £1.8m of venture capital from Close Brothers, which could lead to the creation of up to 100 laboratory jobs.

Novartis is planning to invest £34m at its Grimsby pharmaceuticals plant to manufacture the intermediates for the new Cox 189 pain relief drug.

Unilever is to sell its DiverseyLever commercial cleaning business to Johnson Wax Professional of the US for £1.1bn, in order to reduce debt following the acquisition of Bestfoods.

Intercare is to invest £10m in a new pharmaceuticals contract manufacturing plant in Belgium, to increase production of pre-filled syringes.

Tissue Science Laboratories is planning to raise about £10m in a flotation on Aim, in order to fund the development of a new medical devices manufacturing facility.

Inverness Medical has won permission from Highland Council to expand its biomedical production plant in Inverness, raising hopes that 450 new jobs will be brought to the site.

Goldshield is to acquire the Antigen International, Antigen Overseas and Anpharm subsidiaries of Antigen Holdings of Ireland for £9.4m, in order to gain the distribution rights for a number of sterile pharmaceutical products.

Creative Outsourcing Solutions, the cosmetics and toiletries manufacturer, has undergone a £47m management buy-out backed by Barclays Private Equity, and the deal includes the Revlon plant in Maesteg.

The Scottish Crop Research Institute is seeking outline planning permission for a new science park at Mylnefield and for a mix of housing and business units at Gourdie, in a £60m investment that could create 1,000 jobs.

The Welsh Development Agency is supporting proposals from the University of Wales College of Medicine, Cardiff University and Techniquest to build Wales Gene Park in Cardiff, which could create thousands of biotechnology-related jobs.

Ardana, the reproductive healthcare specialist, has secured £13m of venture capital, and is now looking for up to 15 scientists and new offices on one of Edinburgh's science parks.

ClinPhone, the Nottingham-based supplier of clinical trial management solutions to pharmaceutical companies, has secured a £6m refinancing facility and hopes to create 70 new jobs over the next year.

Amberley has sold its Lawrence Industries mineral and chemicals subsidiary to Phipps & Company for £9.5m.

EMT Healthcare has bought Estchem Wholesale Supplies, the Manchester-based distributor of pharmaceutical products, for undisclosed terms.

Trinity College and Gallaher Estates have announced plans to develop a new science park on the outskirts of Cambridge, which would be linked to the new Oakington-Longstanton settlement and provide up to 6,000 jobs.

CP Pharmaceuticals has started recruiting 25 additional staff to prepare for an increase in production at its pharmaceuticals plant in Wrexham.

Aventis has confirmed plans to sell its agrochemicals division to Bayer of Germany for £4.5bn, which could lead to changes in staffing levels at sites in Norwich and elsewhere in the UK.

Leicester University has announced a £31m expansion plan to build three new research centres in biomedical science, space science and mathematics, which could lead to the creation of hundreds of new jobs.

ICN Pharmaceuticals is setting up a new research centre at the Technium development in Swansea to study the combined use of drugs and laser therapy in the treatment of cancer.

Osmetech has secured £5m of funding from GEM Global Yield Fund of the US to develop gas and odour sensors for medical use.

Inverness Medical is seeking permission to double the size of its base in Inverness, due to rising demand for blood glucose diagnostic systems, which could lead to an increase in the 800-strong workforce.

NMT, the Livingston-based manufacturer of safety syringes, is seeking an estimated £15m of funding to expand the capacity of two production lines.

RiboTargets has raised £32m to fund the expansion of its drug discovery business.

Manro Performance Chemicals, the Stalybridge-based surfactants manufacturer with 125 employees, has been acquired by Stepan Company of the US for undisclosed terms.

Mitchell Cotts has opened a new laboratory at its chemical plant near Huddersfield to produce liquids used in eye drops, and a second laboratory will open next year with the creation of 10 jobs.

Nippon Gohsei of Japan has announced plans to build a £64m chemical plant, producing environmentally friendly packaging for gases and liquids, at the BP Saltend site in Hull, with the creation of 70 jobs.

Celltech is to acquire Thiemann, the German pharmaceuticals marketing company, for £31m, and is also buying an undisclosed stake in Neogenesis of the US and the rights to the drug discovery technology of Abgenix.

Orion Pharma of Finland is to set up a new clinical research department in Nottingham, with the creation of up to 52 jobs over the next few years.

Dechra Pharmaceuticals is planning a £2m expansion at its veterinary products factory in Skipton over the next 18 months.

Applied Biosystems, the US manufacturer of DNA fingerprinting equipment, is setting up a £7m headquarters at the Birchwood Point Business Park in Warrington, which will employ about 200 staff.

Ashfield Healthcare, the supplier of staff to pharmaceutical companies, is to build a new £5.8m headquarters in Ashby de la Zouch by the end of 2002, and staff will be relocated from four existing premises nearby.

Intercare has acquired Federa and Veramic, two Belgian pharmaceutical suppliers with a total workforce of 238, for £14m.

Acordis has sold its Leek-based fine chemicals business to Tessenderlo of Belgium for undisclosed terms, which will involve the transfer of 90 jobs.

Pharmacopeia of the US is to set up a European headquarters for its Accelrys pharmaceutical software subsidiary at a 42,000 sq ft site on the Cambridge Science Park in early 2002.

Shire Pharmaceuticals has raised £280m from an issue of convertible bonds, in order to fund the acquisition of speciality pharmaceutical products and support its expansion into Japan and Europe.

Bomb Cosmetics is creating 100 new jobs at its cosmetics factory in Bournemouth, having won contracts worth £1m from three major retail chains.

Pfizer has confirmed plans to relocate a major part of its sales and marketing operation from Sandwich to Walton-on-the-Hill, near Tadworth, in December, where it will initially employ 425 staff.

Yule Catto has bought the remaining 50% stake in Harlow Chemical Company, the supplier of emulsions, from Clariant for £55m, and now plans to expand the business into continental Europe.

Provalis, the distributor of medical devices and pharmaceutical products, is to set up a new 11,000 sq ft warehouse and production facility near its Deeside headquarters in September.

Powderject has announced plans to invest £13m at its Evans Vaccines plant in Speke, in order to increase production of flu vaccines.

Hays has sold its non-core chemicals business to a management buy-in team called Albion Chemicals for £107m, which will involve the transfer of 850 staff at 16 depots throughout the country.

Henderson Morley is planning to raise £1.3m in a flotation on Aim in order to fund the development of new technology to treat viruses.

BioVex has raised £10m in a private share placing to fund the development of its Oxford-based gene therapy business.

Glasgow University is linking up with Imperial College and the Generics Group to launch a new spin out company called Adaptive Screening, which aims to speed up the identification of compounds for the development of new drugs.

Procter & Gamble is to invest £9m at its Longbenton Technical Centre in North Tyneside over the next three years to develop new laundry products, and has secured a £1.8m regional selective assistance grant from the DTI.

BP is to sell two Burmah Castrol chemical businesses - Foseco in the West Midlands and Chem-Trend in the US - to Cinven for £240m.

PPL Therapeutics is looking to raise about £20m in a share issue to fund the development of its new drug manufacturing facilities.

Bespak is in discussions to sell its King's Lynn-based personal care business, which employs 70 people, as part of a strategy to focus on the development of its drug delivery business.

CeNes Pharmaceuticals has acquired Management Dynamics Cambridge, a specialist organisational psychology company, and merged it with its own cognition division to create a new business called Cambridge Cognition.

Powderject Pharmaceuticals has acquired SBL Vaccin, the Swedish vaccines company, for £35m, and is now looking to sell the rights to its needleless syringe.

Inpharmatica is to raise £31m in a share placing in order to fund the development of its drug discovery business.

LGC has acquired Promochem of Germany for £10m, in order to expand its pharmaceutical testing services in a number of European countries.

Evolutec is planning to raise £5m to fund the expansion of its Oxford-based biotechnology business, which will involve the development of new allergy treatments derived from the saliva of ticks.

Hodgson Chemicals has unveiled plans for a £10m expansion project in Selby that could lead to a new global technical service centre for leather manufacture, additional production capacity and 40 new jobs.

Interpon Powder Coatings, the Akzo Nobel subsidiary, is to set up an international headquarters at its Gateshead site, in order to provide administration services to 2,300 employees and 24 paint plants worldwide.

Johnson Matthey is planning to acquire Meconic, the Edinburgh-based manufacturer of pharmaceutical chemicals, for £147m.

Amedis Pharmaceuticals has secured £4m of funding from Merlin Biosciences Fund and other venture capitalists to expand its drug development business.

KS Biomedix is planning to acquire Avicenna Medica of Canada for £42m, partly funded by a £16m share placing.

Oxford Glycosciences and Marconi are forming a £30m joint venture called Confirmant to develop a database of human proteins, and they will also offer IT outsourcing services to pharmaceutical and biotechnology companies.

Norbrook Laboratories is to recruit 20 additional scientists at the former Scotia pharmaceuticals plant in Carlisle, and is also in negotiations to set up a chemical plant on a 40-acre site in Newcastle-upon-Tyne.

Cyclacel is planning to raise £34m in a share placing to fund the development of anti-cancer drugs, and is expected to seek a partnership with a large pharmaceutical group after the drugs have undergone clinical trials.

KPMG has completed a feasibility study into setting up a £22m National Gene Centre in Leicester, which would be developed by a partnership of health, industry and local government groups.

Gower Chemicals has won a £0.2m Regional Selective Assistance grant to go towards a £0.8m expansion at its chemicals plant in Swansea, which will safeguard 60 jobs.

Gemini Genomics is to be acquired by Sequenom, the US gene sequencing company, for £140m.

BioFocus is to acquire Cambridge Drug Discovery, the drug screening specialist, for £27m, in order to offer a wider range of services to the pharmaceutical industry.

R&D Systems, the US distributor of biomedical research products, has set up a new £3m European headquarters in Abingdon, and expects to add to the 50 existing staff this year.

Cambridge Antibody Technology is forming an alliance with Immunex of the US to develop antibody-based treatments for auto-immune and inflammatory disorders.

GW Pharmaceuticals is planning to raise £16m in a flotation on Aim in order to fund the development of new medicines derived from cannabis.

Cytomyx is planning to raise £3m in a flotation on Aim, in order to expand its drug research business and invest in genomic and proteomics technology.

PA Consulting is to provide £10m of funding to a new biotechnology company called Meridica, which will employ 30 people at its Cambridgeshire base to develop a new asthma inhaler.

Pfizer has announced plans to build a £134m pharmaceuticals research centre at Sandwich in Kent, with the creation of 400 jobs.

Strakan Group has raised £30m in a private equity investment to fund the development of new drugs for bone and skin disease, and expects to create about 20 jobs at its Galashiels base.

Walter Lilly has been awarded a £10m contract to extend the Centre for Gene Function at Oxford University, and will start work next month.

AstraZeneca is to open a £69m pharmaceuticals plant in the Wuxi New District of China, where it will employ 280 people manufacturing products for the domestic market.

LGC is planning to set up a multi-million pound DNA profiling laboratory in Runcorn, creating scores of scientific jobs.

Clariant has sold AB Vickers, the Burton-based supplier of brewing industry chemicals, to Lallemand of Canada for undisclosed terms.

Phoenix Healthcare Distribution has acquired Tatfords, the Cosham-based pharmaceuticals wholesaler, for £8m.

Huntsman is to recruit 10 new workers at its recently-acquired Rhodia chemical plant in Whitehaven.

Bioglan is planning to buy or set up new companies in Italy and Spain later this year, as part of a strategy to expand its speciality pharmaceuticals business across Europe.

South Gloucestershire Council is considering plans from Bristol University and London-based Howsmoor Developments for the development of an international science park on a 70-acre site at Emersons Green, which could create 5,000 jobs.

FW Pharma Systems, the developer of administrative software for the pharmaceuticals industry, is relocating its Birmingham office and 90 staff to Brindley Place.

AstraZeneca is to acquire the rights to develop cancer treatment based on the work of Cyclacel in Dundee, in a £8m deal.

North West Development Agency has announced plans for the development of a £8m science park at the Daresbury Laboratory in Warrington, which will involve new offices and laboratory facilities on a 13-acre site.

The University of St Andrews has been awarded £2.3m from the DTI and Wellcome Trust-backed Joint Infrastructure Fund to set up new drug discovery facilities.

Umist is to build a new £28m disease research complex in Manchester, bringing together experts from across the university's biomedical, analytical science and chemistry departments.

Celltech is planning to increase its US salesforce by 40% to 400, having won approval to launch its Metadate hyperactivity drug.

Watts Blake Bearne is to relocate its corporate headquarters from Newton Abbot to sister company Sibelco Minerals & Chemicals in Cheshire, with the loss of up to 70 jobs.

Alcan Chemicals Europe is transferring its Technical Group from Banbury to Burntisland in Fife with the creation of a small number of jobs, in order to further the development of fire retardants and powders for refractories and ceramics.

Ascot, the chemical engineering group, has accepted a £305m takeover bid from Dow Chemical of the US, and has also announced the sale of Nationwide Refrigeration Supplies to Wolseley for £22m.

Infineum, the petrochemical additives company, is planning to build a £12m technology centre at Milton near Abingdon.

AstraZeneca has announced plans to invest £110m in new laboratory and office facilities at its Alderley Park research site near Macclesfield.

Alliance UniChem is planning to invest a further £6m in internet activities this year, and will launch its web-based pharmaceuticals trading system into more countries.

Pearl Paints has been bought out of receivership by a former director, saving 45 jobs in South Wales, and the company will be renamed Pearl Technical Coatings.

Oxford Glycosciences is planning to expand its biotechnology business into drug development, and is seeking potential partners in order to minimise the infrastructure costs.

Celltech is looking to strengthen its biotechnology business by making technology and product acquisitions, and is particularly interested in expanding in the US.

Reckitt Benckiser is to acquire Oxy, the South Korean manufacturer of household and personal care products, for £87m.

Alberto Culver is considering plans to double production at its cosmetics factory in Swansea, with the creation of hundreds of new jobs.

Celltech has announced a licensing deal with Pharmacia of the US for the development of a treatment for rheumatoid arthritis, and will receive an upfront payment of £34m.

Oxford Biomedica is planning to raise up to £30m in a share offer in order to fund international expansion and clinical trials for new gene therapy-based products.

Glasgow University, Strathclyde University and Edinburgh University are to benefit from a £90m investment fund to develop drugs, in a new scheme unveiled by the Scottish Executive.

First Water is looking to recruit 10 scientists for a new £3m research centre being set up in Ramsbury, Wiltshire, where it will develop specialised dressings for burns and other skin treatments.

Novartis has opened a £40m research centre in Horsham to develop treatments for respiratory diseases, and the site will employ 180 scientists.

Hunter-Fleming has acquired AEGIS, the pharmaceutical research company spun out of the University of Bristol, for £3m.

Pharmaceutical Profiles is to open a new £2.5m research facility at Ruddington Fields in Nottingham in March, including three clinical imaging suites, laboratories, offices and a lecture theatre.

Xenova is to acquire Cantab Pharmaceuticals, the Cambridge-based vaccines company, for £53m.

Procter & Gamble has confirmed plans to build a second multi-million pound office complex at its headquarters in North Tyneside, in order to house 300 staff by March 2002.

Cellmark Diagnostics, the Abingdon-based DNA testing company, has been bought by Orchid BioSciences of the US for undisclosed terms.

Profiad has raised £5m from Mercury Private Equity to fund the expansion of its drug research business in Reading.

Merck Sharp & Dohme is planning a £170m expansion at its pharmaceuticals site in Hoddesdon over the next 15 years, which will involve a new laboratory, additional office space and the creation of 350 jobs.

Celltech has sold Armstrong, the supplier of aerosol inhalation products, to Andrx Corporation of the US for £12m.

Aortech is planning to raise £64m in a share issue in order to fund acquisitions and the development of new healthcare devices.

Galen is looking to expand its pharmaceuticals business in continental Europe and the US, but its services division, which prepares medicines for clinical trials, is now regarded as non-core.

Celltech has formed an alliance with Abgenix of the US that will give it access to new technology for the development of antibody-based medicines.

The University of Birmingham has been awarded £45m by the Joint Infrastructure Fund to develop its position as a major centre for international research, including the creation of a national biomolecular research unit.

Whatman is to acquire HemaSure, the US producer of blood filtration products, for up to £17m.

Genzyme of the US is to build a £37m biotechnology production plant in Haverhill to meet rising demand for its Renegal kidney drug, with the creation of 200 jobs.

ICI is planning to sell Cheshire-based Eutech Engineering Solutions, which employs 550 people, to Swiss technology firm ABB.

Protherics has raised £3.1m in a share placing in order to fund the expansion of its pharmaceutical production facilities.

PPL Therapeutics has confirmed plans to build a £42m bio-manufacturing facility at the Gowkley Moss Farm site near Penicuik, Midlothian, where it will employ up to 250 people.

Pfizer is to close its laboratories at Addenbrooke's Hospital in Cambridge this year, in order to relocate 100 scientists to its research campus in Kent.

Syngenta is seeking permission to open a £50m agrochemicals plant at Grangemouth in May to produce a new fungicide called picoxystrobin.

Nova Chemicals of Canada is setting up an operating centre for its European styrenics business near Manchester Airport, with the creation of 50 jobs.

Babraham Institute has selected Churchmanor Estates as its partner for the development of a £50m biotechnology research campus, which will provide new laboratory facilities for start-up companies in the Cambridge area.

AstraZeneca has sold its dental anaesthetics business to Dentsply International of the US for £91m.

AstraZeneca is to invest £37m in the expansion of its Macclesfield plant, due to rising demand for its Seroquel treatment for schizophrenia.

York Inward Investment Board has announced that two US companies are setting up UK headquarters in York - protective coatings manufacturer Williams Hayward and audio-visual components supplier Autopatch.

Oxxon Pharmaccines has raised £4.7m to fund the development of in-house research facilities and clinical trials of its new therapeutic vaccines.

ICI has raised £52m from the sale of its UK-based methanol business to Methanex of Canada and the sale of its share in the Phillips-Imperial Petroleum joint venture to Petroplus.

Medical Solutions has acquired Quinoderm, the producer of dermatology products, for £3.7m, and is now seeking further acquisitions.

Oxford Biomedica is seeking a partner to fund the development of its TroVax cancer vaccine, and is also planning to seek a listing on London's main market.

Albright & Wilson, the manufacturer of cleaning fluids, is being sold by Rhodia of France to Huntsman of the US for undisclosed terms, and its Whitehaven plant will be jointly operated by Huntsman and Rhodia's phosphates division.

Scottish Enterprise has proposed plans to develop a biomedical research park in the Little France area of Edinburgh, and Deloitte & Touche has won a contract to design the blueprint.